glucagon-like peptide 1 , human acetate

Glucagon-like peptide 1 (1-37), human acetate is a highly potent the GLP-1 receptor agonist.

Retatrutide acetate (LY3437943) is a peptide and triple agonist for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), exhibiting potent inhibitory effects on human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM respectively; it is utilized in obesity research [1].

Exenatide acetate is a polypeptide hormone composed of 39 amino acids. As a glucagon-like peptide-1 (GLP-1) receptor agonist with an IC50 of 3.22 nM, it is indicated for the treatment of insulinoma and type 2 diabetes. Exendin acetate promotes migration, sprouting, and nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs) in vitro. It exhibits cytotoxicity towards MCF-7 cells and provides protective effects against ischaemic injury in a mouse hindlimb model.

GLP-1(7-36), amide acetate is a derivative of GLP-1 peptide (glucagon-like peptide-1).GLP-1(7-36), amide is able to activate the GLP-1 receptor, which has the ability to promote insulin secretion and inhibit glucagon secretion, with the potential to treat type 2 diabetes mellitus and obesity.